|1.||Lamb, Janice: 3 articles (03/2007 - 03/2007)|
|2.||Ellis, Amanda: 3 articles (03/2007 - 03/2007)|
|3.||Layton, Gary: 2 articles (03/2007 - 03/2007)|
|4.||Meglasson, Martin D: 2 articles (09/2005 - 12/2003)|
|5.||Rice, Kenner C: 1 article (08/2007)|
|6.||Newman, Amy Hauck: 1 article (08/2007)|
|7.||Husbands, Stephen M: 1 article (08/2007)|
|8.||Chauvignac, Cédric: 1 article (08/2007)|
|9.||Grundt, Peter: 1 article (08/2007)|
|10.||Chen, Jianyong: 1 article (08/2007)|
|1.||Parkinson Disease (Parkinson's Disease)
03/01/2007 - "Given data published in Parkinson's disease, the dose range of sumanirole selected here may have been too low. "
07/01/1997 - "6. In conclusion, U-95666E may have potential for the treatment of Parkinson's Disease and associated anxiety."
03/15/2007 - "A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease."
03/15/2007 - "Statistical significance (P < 0.0001) was achieved when both sumanirole and ropinirole groups were compared with placebo, with mean differences of -7.7 and -8.8 on combined sum of the Unified Parkinson's Disease Rating Scale (UPDRS) part II (average on and off) and part III total scores at the end of maintenance. "
03/15/2007 - "Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease."
|2.||Restless Legs Syndrome (Restless Legs)
03/01/2007 - "Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study."
03/01/2007 - "To compare the efficacy, safety and tolerability of sumanirole with placebo in patients with idiopathic restless legs syndrome (RLS). "
08/01/2007 - "D3-preferring agonists induced yawning at lower doses than those required to induce hypothermia and the D2-preferring agonist, sumanirole, induced hypothermia at lower doses than were necessary to induce yawning. "
08/01/2007 - "The ability of D3-selective and D2-selective antagonists to inhibit the induction of yawning and hypothermia were assessed and a series of D2/D3 antagonists were characterized with respect to their ability to alter yawning induced by a low and high dose of PD-128,907 and sumanirole-induced hypothermia. "
|2.||Dopamine Agonists (Dopamine Agonist)
|4.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|6.||Levodopa (L Dopa)
|7.||Ethyl Ether (Ether)